Release Time：2020-04-03 Source：Derrick medical's announcement on March 30 night, publicly announced plans to issue convertible company bonds to raise funds not more than RMB 700 million yuan, total to raise funds will be used for industrialization of chemiluminescence immunoassay, biochemical analysis and urine production line technological transformation, blood coagulation analysis research and development of industrialization, POCT and supplement working capital and other projects. It is worth noting that this offering is the first refinancing launched by deary medical since it went public in September 2014. This fundraising is based on the company's existing main business, combined with the needs of future market development, to improve the production technology and expand the capacity of existing competitive products, to accelerate the industrialization of new products through the combination of production and research, and to expand new business areas. This refinancing can strengthen the company's competitive advantage, enhance the company's sustainable profitability, so as to provide important support and guarantee for the company's subsequent development. Derrick medical attention mainly the pace of growth is moderate, not blind expansion, instruments and reagents, test paper to realize the balanced development, at present, the company products from their initial urine analysis test paper until now products cover "biochemistry, urine, blood cell analysis, chemiluminescence immunoassay, laboratory secretions, blood coagulation analysis and integration of department of gynaecology" IVD 7 big niche, users in more than 100 countries and regions. According to the company's 2019 annual performance bulletin, the total operating revenue in the past five years increased from 486 million yuan to 1.09 billion yuan, with a compound annual growth rate of 15.73%. The net profit of the company was increased from 101 million yuan to 232 million yuan, with a compound annual growth rate of 18.10%. Currently, the company's total market value is about 6 billion yuan, and the p/e ratio is 26.08, lower than the average level of the same industry.